Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction.
暂无分享,去创建一个
Hyung-Suk Kim | H. Rockman | S. N. Naga Prasad | L. Mao | Zhen Yan | O. Smithies | T. Noma | C. Perrino
[1] W. Koch,et al. Genetic Alterations That Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall Stress , 2002, Circulation.
[2] R. S. Williams,et al. Skeletal muscle adaptation in response to voluntary running in Ca2+/calmodulin-dependent protein kinase IV-deficient mice. , 2004, American journal of physiology. Cell physiology.
[3] C. Parent. Faculty Opinions recommendation of PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. , 2004 .
[4] S. Yusuf,et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[5] R. Lefkowitz,et al. When 7 transmembrane receptors are not G protein-coupled receptors. , 2005, The Journal of clinical investigation.
[6] J. Knowles,et al. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. , 2001, The Journal of clinical investigation.
[7] R. Kitsis,et al. The MEK1–ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice , 2000, The EMBO journal.
[8] A. Zeiher,et al. Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. , 2002, The Journal of clinical investigation.
[9] S. Houser,et al. Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. , 1998, Circulation.
[10] Lan Mao,et al. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. , 2001, Journal of the American College of Cardiology.
[11] M. Caron,et al. Agonist-dependent Recruitment of Phosphoinositide 3-Kinase to the Membrane by b-Adrenergic Receptor Kinase 1 A ROLE IN RECEPTOR SEQUESTRATION* , 2001 .
[12] M. Caron,et al. Agonist-dependent Recruitment of Phosphoinositide 3-Kinase to the Membrane by β-Adrenergic Receptor Kinase 1 , 2001, The Journal of Biological Chemistry.
[13] W. Koch,et al. Vascular rarefaction in peripheral skeletal muscle after experimental heart failure. , 2003, American journal of physiology. Heart and circulatory physiology.
[14] P. Kang,et al. Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[15] R. Lefkowitz,et al. Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[16] Anthony J. Muslin,et al. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. , 1999, The Journal of clinical investigation.
[17] J. Knowles,et al. Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis. , 2002, American journal of physiology. Heart and circulatory physiology.
[18] M. Cho,et al. Defective β-Adrenergic Receptor Signaling Precedes the Development of Dilated Cardiomyopathy in Transgenic Mice with Calsequestrin Overexpression* , 1999, The Journal of Biological Chemistry.
[19] J. Hedner,et al. Impairment of vascular endothelial function and left ventricular filling : association with the severity of apnea-induced hypoxemia during sleep. , 2001, Chest.
[20] S. Vatner,et al. The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. , 2002, The Journal of clinical investigation.
[21] F. Meerson. Compensatory Hyperfunction of the Heart and Cardiac Insufficiency , 1962, Circulation research.
[22] C W Whitney,et al. Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. , 2001, American journal of respiratory and critical care medicine.
[23] F. Abboud,et al. Sympathetic neural mechanisms in obstructive sleep apnea. , 1995, The Journal of clinical investigation.
[24] Dianqing Wu,et al. Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. , 2003, The Journal of clinical investigation.
[25] J. Ross,et al. Loss of a gp130 Cardiac Muscle Cell Survival Pathway Is a Critical Event in the Onset of Heart Failure during Biomechanical Stress , 1999, Cell.
[26] E. Olson,et al. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. , 1999, Circulation research.
[27] R. Quaife,et al. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. , 2002, The New England journal of medicine.
[28] R. Lefkowitz,et al. Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[29] G. Dorn,et al. Protein kinase cascades in the regulation of cardiac hypertrophy. , 2005, The Journal of clinical investigation.
[30] N. Christensen,et al. Sympathetic nervous activity during exercise. , 1983, Annual review of physiology.
[31] S. Gordon. Faculty Opinions recommendation of Protein kinase activity of phosphoinositide 3-kinase regulates beta-adrenergic receptor endocytosis. , 2005 .
[32] C. Kahn,et al. Regulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling Pathways , 2002, Cell.
[33] Paul A. Overbeek,et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice , 2000, Nature Medicine.
[34] M. Nieminen,et al. Prognostic significance of left ventricular mass change during treatment of hypertension. , 2004, JAMA.
[35] B. Groves,et al. Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. , 1997, The Journal of clinical investigation.
[36] M. Caron,et al. Phosphoinositide 3-kinase regulates β2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/β-arrestin complex , 2002, The Journal of cell biology.
[37] L. Silengo,et al. PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects , 2004, Cell.
[38] Robert J. Lefkowitz,et al. Seven-transmembrane-spanning receptors and heart function , 2002, Nature.
[39] I. Shiojima,et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. , 2005, The Journal of clinical investigation.
[40] J. Ross,et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[41] D. Levy,et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.
[42] J. Weiss,et al. Time constant of isovolumic pressure fall: determinants in the working left ventricle. , 1978, The American journal of physiology.
[43] L. Leinwand,et al. Myosin heavy chain gene expression in human heart failure. , 1997, The Journal of clinical investigation.
[44] H. Gavras,et al. Conditioning effects of chronic infusions of dobutamine. Comparison with exercise training. , 1979, The Journal of clinical investigation.
[45] R. Lefkowitz,et al. Level of &bgr;-Adrenergic Receptor Kinase 1 Inhibition Determines Degree of Cardiac Dysfunction After Chronic Pressure Overload–Induced Heart Failure , 2005 .
[46] Luigi Fratta,et al. Melusin, a muscle-specific integrin β1–interacting protein, is required to prevent cardiac failure in response to chronic pressure overload , 2003, Nature Medicine.
[47] J. Ross,et al. Hyperfunction with normal inotropic state of the hypertrophied left ventricle. , 1977, The American journal of physiology.
[48] Michael S Lauer,et al. Left ventricular hypertrophy: the next treatable, silent killer? , 2004, JAMA.
[49] W. Koch,et al. Mechanism of β-Adrenergic Receptor Desensitization in Cardiac Hypertrophy Is Increased β-Adrenergic Receptor Kinase* , 1997, The Journal of Biological Chemistry.
[50] H. Suga,et al. Heart size-independent analysis of myocardial function in murine pressure overload hypertrophy. , 2002, American journal of physiology. Heart and circulatory physiology.
[51] H. Rockman,et al. Restoration of &bgr;-Adrenergic Receptor Signaling and Contractile Function in Heart Failure by Disruption of the &bgr;ARK1/Phosphoinositide 3-Kinase Complex , 2005, Circulation.
[52] S. V. Prasad,et al. Protein kinase activity of phosphoinositide 3-kinase regulates β-adrenergic receptor endocytosis , 2005, Nature Cell Biology.
[53] L. Leinwand,et al. Myosin heavy chain isoform expression in the failing and nonfailing human heart. , 2000, Circulation research.
[54] K. Chien,et al. Erratum: Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy (Proc. Natl. Acad. Sci. USA (September 1991) 88 (8277-8281)) , 1991 .
[55] E. Olson,et al. Hypertrophy of the heart: a new therapeutic target? , 2004, Circulation.
[56] Robert J. Lefkowitz,et al. Transduction of Receptor Signals by ß-Arrestins , 2005, Science.
[57] W. Gaasch,et al. Myocardial relaxation. II. Hemodynamic determinants of rate of left ventricular isovolumic pressure decline. , 1980, The American journal of physiology.
[58] H. Rockman,et al. Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. , 2005, Journal of the American College of Cardiology.
[59] S. Kudoh,et al. Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II , 2004, Nature Cell Biology.